[{"address1": "15 Crosby Drive", "city": "Bedford", "state": "MA", "zip": "01730", "country": "United States", "phone": "781 357 4000", "fax": "781 275 7562", "website": "https://www.ocutx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.", "fullTimeEmployees": 267, "companyOfficers": [{"maxAge": 1, "name": "Mr. Donald  Notman Jr.", "title": "Chief Financial Officer", "fiscalYear": 2023, "totalPay": 679770, "exercisedValue": 0, "unexercisedValue": 90888}, {"maxAge": 1, "name": "Dr. Jeffrey S. Heier M.D.", "age": 62, "title": "Chief Scientific Officer", "yearBorn": 1961, "fiscalYear": 2023, "totalPay": 86162, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Rabia Gurses Ozden M.D.", "age": 54, "title": "Chief Medical Officer", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 687349, "exercisedValue": 0, "unexercisedValue": 38971}, {"maxAge": 1, "name": "Dr. Pravin U. Dugel M.D.", "age": 59, "title": "Executive Chairman, President & CEO", "yearBorn": 1964, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Karen-Leigh  Edwards M.B.A., Ph.D.", "title": "Chief Operations Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Peter K. Jarrett Ph.D.", "age": 66, "title": "Chief Technology Officer", "yearBorn": 1957, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. William S. Slattery Jr.", "title": "Vice President of Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Philip C. Strassburger Esq.", "age": 63, "title": "General Counsel", "yearBorn": 1960, "fiscalYear": 2023, "totalPay": 282613, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. William H. Ransone II", "title": "Vice President of Global Sales & Marketing", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Tracy  Smith", "title": "Vice President of Human Resources", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 6, "compensationRisk": 10, "shareHolderRightsRisk": 7, "overallRisk": 9, "governanceEpochDate": 1714521600, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 5.8, "open": 5.83, "dayLow": 5.7112, "dayHigh": 5.89, "regularMarketPreviousClose": 5.8, "regularMarketOpen": 5.83, "regularMarketDayLow": 5.7112, "regularMarketDayHigh": 5.89, "beta": 1.463, "forwardPE": -5.9742265, "volume": 1276794, "regularMarketVolume": 1276794, "averageVolume": 2539746, "averageVolume10days": 2033990, "averageDailyVolume10Day": 2033990, "bid": 5.76, "ask": 5.84, "bidSize": 700, "askSize": 400, "marketCap": 897581696, "fiftyTwoWeekLow": 1.995, "fiftyTwoWeekHigh": 11.31, "priceToSalesTrailing12Months": 14.998942, "fiftyDayAverage": 7.0386, "twoHundredDayAverage": 5.053375, "currency": "USD", "enterpriseValue": 489098272, "profitMargins": -1.92614, "floatShares": 126220526, "sharesOutstanding": 154888992, "sharesShort": 21076296, "sharesShortPriorMonth": 11808322, "sharesShortPreviousMonthDate": 1711584000, "dateShortInterest": 1714435200, "sharesPercentSharesOut": 0.1362, "heldPercentInsiders": 0.00708, "heldPercentInstitutions": 0.80235, "shortRatio": 8.08, "shortPercentOfFloat": 0.1368, "impliedSharesOutstanding": 160230000, "bookValue": 2.637, "priceToBook": 2.197573, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -115266000, "trailingEps": -1.12, "forwardEps": -0.97, "enterpriseToRevenue": 8.173, "enterpriseToEbitda": -5.556, "52WeekChange": -0.09311426, "SandP52WeekChange": 0.26137078, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "OCUL", "underlyingSymbol": "OCUL", "shortName": "Ocular Therapeutix, Inc.", "longName": "Ocular Therapeutix, Inc.", "firstTradeDateEpochUtc": 1406295000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "b2e86f5b-6ae3-30af-bdc2-4b9ad5a2cf9e", "messageBoardId": "finmb_41955650", "gmtOffSetMilliseconds": -14400000, "currentPrice": 5.795, "targetHighPrice": 22.0, "targetLowPrice": 7.0, "targetMeanPrice": 14.5, "targetMedianPrice": 14.5, "recommendationMean": 1.6, "recommendationKey": "buy", "numberOfAnalystOpinions": 8, "totalCash": 482888000, "totalCashPerShare": 3.118, "ebitda": -88030000, "totalDebt": 74405000, "quickRatio": 20.966, "currentRatio": 21.394, "totalRevenue": 59843000, "debtToEquity": 18.237, "revenuePerShare": 0.64, "returnOnAssets": -0.17125, "returnOnEquity": -0.55192, "freeCashflow": -57922376, "operatingCashflow": -84148000, "revenueGrowth": 0.105, "grossMargins": -0.21043, "ebitdaMargins": -1.4710201, "operatingMargins": -2.14004, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-05-26"}]